
  
    
      
        Background_NNP
        Cytomegalovirus_NNP (_( CMV_NNP )_) and_CC Epstein-_NNP Barr_NNP virus_NN (_( EBV_NNP )_) ,_, in_IN
        immunocompetent_NN individuals_NNS ,_, are_VBP etiologically_RB associated_VBN
        with_IN infectious_JJ mononucleosis_NNS as_RB well_RB as_IN other_JJ disease_NN
        presentations_NNS and_CC malignancies_NNS [_NN 1_CD 2_CD ]_NN ._. Once_RB a_DT person_NN has_VBZ
        recovered_VBN from_IN an_DT active_JJ herpesvirus_JJ infection_NN ,_, it_PRP will_MD
        establish_VB a_DT latent_NN infection_NN ._. Maintenance_NNP of_IN viral_JJ latency_NN
        is_VBZ primarily_RB determined_VBN by_IN the_DT immune_JJ status_NN of_IN the_DT host_NN ;_:
        but_CC there_EX are_VBP other_JJ factors_NNS that_WDT can_MD contribute_VB to_TO
        herpesviral_NN reactivation_NN [_NN 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN ._.
        There_EX are_VBP numerous_JJ studies_NNS observing_VBG CMV_NNP and_CC EBV_NNP
        reactivation_NN in_IN immunosuppressed_JJ patients_NNS ._. CMV_NNP is_VBZ the_DT most_RBS
        important_JJ pathogen_NN among_IN these_DT patients_NNS and_CC the_DT virus_NN can_MD
        cause_VB both_DT direct_JJ and_CC indirect_JJ effects_NNS [_NN 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD ]_NN
        ._. Among_IN solid_JJ organ_NN transplant_NN recipients_NNS ,_, the_DT effects_NNS of_IN
        CMV_NNP disease_NN are_VBP similar_JJ among_IN all_DT patients_NNS ,_, with_IN the_DT
        exception_NN being_VBG the_DT effect_NN on_IN the_DT transplanted_VBN organ_NN [_NN 10_CD
        14_CD 15_CD 16_CD 17_CD ]_NN ._. The_DT most_RBS common_JJ disease_NN presentation_NN of_IN CMV_NNP
        in_IN AIDS_NNP patients_NNS is_VBZ retinitis_NNS [_NN 8_CD 11_CD ]_NN ._. The_DT significance_NN
        of_IN CMV_NNP disease_NN in_IN transplant_NN and_CC HIV_NNP infected_JJ individuals_NNS
        goes_VBZ much_JJ further_RB than_IN the_DT direct_JJ pathological_JJ effects_NNS
        because_IN CMV_NNP has_VBZ been_VBN shown_VBN to_TO be_VB an_DT immune_JJ modulator_NN and_CC
        may_MD contribute_VB significantly_RB to_TO the_DT net_JJ immunosuppressive_JJ
        status_NN of_IN the_DT patient_NN [_NN 11_CD ]_NN ._. This_DT immunomodulation_NN would_MD
        therefore_RB increase_VB the_DT susceptibility_NN to_TO superinfections_NNS
        from_IN other_JJ pathogens_NNS ._.
        Oral_NNP hairy_JJ leukoplakia_NN ,_, caused_VBN by_IN EBV_NNP ,_, can_MD be_VB present_JJ in_IN
        25_CD %_NN of_IN HIV_NNP infected_JJ individuals_NNS [_NN 8_CD 18_CD ]_NN ._. Other_JJ clinical_JJ
        presentations_NNS have_VBP been_VBN observed_VBN as_RB well_RB [_NN 8_CD 19_CD 20_CD ]_NN ._. Birx_NNP
        et_CC al_NN ._. observed_VBD that_IN patients_NNS with_IN AIDS_NNP or_CC AIDS-related_NNP
        disorders_NNS have_VBP a_DT defect_NN in_IN the_DT regulation_NN of_IN EBV_NNP infected_JJ
        B-_NNP cells_NNS and_CC these_DT patients_NNS have_VBP high_JJ circulating_VBG numbers_NNS of_IN
        these_DT infected_JJ cells_NNS [_NN 21_CD ]_NN ._. Post-transplant_NNP
        lymphoproliferative_JJ disorder_NN (_( PTLD_NNP )_) results_NNS from_IN the_DT
        uncontrolled_JJ lymphoproliferation_NN of_IN EBV_NNP infected_JJ B-_NNP cells_NNS in_IN
        transplant_NN patients_NNS [_NN 22_CD 23_CD ]_NN ._. There_EX are_VBP many_JJ known_VBN
        factors_NNS for_IN the_DT development_NN of_IN PTLD_NNP ,_, among_IN which_WDT is_VBZ the_DT
        presence_NN of_IN an_DT active_JJ CMV_NNP infection_NN [_NN 13_CD 19_CD 22_CD 23_CD 24_CD ]_NN
        ._.
        Many_JJ studies_NNS have_VBP focused_VBN upon_IN the_DT presence_NN of_IN a_DT single_JJ
        herpesvirus_JJ in_IN the_DT transplant_NN or_CC AIDS_NNP patient_NN [_NN 8_CD 9_CD 10_CD ]_NN ._.
        There_EX are_VBP fewer_JJR studies_NNS examining_VBG virus-virus_JJ interactions_NNS
        and_CC the_DT effect_NN they_PRP may_MD have_VB on_IN each_DT other_JJ ._. Although_IN
        several_JJ investigators_NNS have_VBP focused_VBN upon_IN the_DT relationship_NN of_IN
        human_JJ herpesvirus-_NN 6_CD (_( HHV-_NNP 6_CD )_) (_( same_JJ herpesvirus_JJ subfamily_RB as_IN
        CMV_NNP )_) and_CC HIV_NNP [_NN 25_CD 26_CD 27_CD 28_CD 29_CD ]_NN ,_, studies_NNS dealing_VBG with_IN
        potential_JJ herpesvirus-herpesvirus_JJ interactions_NNS are_VBP very_RB
        limited_JJ ._. Such_JJ studies_NNS would_MD be_VB interesting_JJ since_IN CMV_NNP
        infection_NN has_VBZ been_VBN suggested_VBN as_IN a_DT risk_NN factor_NN for_IN the_DT
        development_NN of_IN PTLD_NNP [_NN 22_CD 24_CD ]_NN ._. Investigators_NNS have_VBP showed_VBN
        that_IN a_DT large_JJ percentage_NN of_IN transplant_NN patients_NNS who_WP had_VBD
        developed_VBN PTLD_NNP also_RB had_VBD CMV_NNP disease_NN [_NN 22_CD 30_CD ]_NN ._. In_IN addition_NN
        to_TO CMV_NNP being_VBG implicated_VBN as_IN a_DT factor_NN for_IN the_DT development_NN of_IN
        PTLD_NNP ,_, serological_JJ studies_NNS have_VBP shown_VBN that_IN patients_NNS with_IN an_DT
        active_JJ CMV_NNP infection_NN experienced_VBD a_DT serological_JJ profile_NN of_IN
        EBV_NNP reactivation_NN [_NN 22_CD 31_CD 32_CD ]_NN ._. Cross_NNP reactivities_NNS between_IN
        the_DT two_CD viruses_NNS were_VBD ruled_VBN out_IN as_IN a_DT cause_NN for_IN the_DT observed_VBN
        immunoreactivations_NNS ._.
        One_CD study_NN performed_VBN 
        in_IN vitro_NN superinfections_NNS of_IN EBV_NNP
        positive_JJ cell_NN lines_NNS (_( Akata_NNP ,_, Raji_NNP ,_, and_CC P_NN 3_CD HR-_NNP 1_LS )_) with_IN HHV-_NNP 6_CD ._.
        EBV_NNP reactivation_NN was_VBD observed_VBN to_TO occur_VB in_IN those_DT cell_NN lines_NNS
        that_WDT were_VBD superinfected_JJ with_IN HHV-_NNP 6_CD and_CC the_DT authors_NNS
        hypothesized_VBN that_IN there_EX was_VBD a_DT direct_JJ effect_NN of_IN HHV-_NNP 6_CD on_IN EBV_NNP
        reactivation_NN [_NN 33_CD ]_NN ._. A_DT more_RBR recent_JJ study_NN by_IN Vieira_NNP et_CC al_NN ._.
        was_VBD able_JJ to_TO show_VB human_JJ herpesvirus-_NN 8_CD (_( HHV-_NNP 8_CD )_) activation_NN of_IN
        lytic_JJ replication_NN by_IN CMV_NNP [_NN 34_CD ]_NN ._. HHV-_NNP 8_CD is_VBZ in_IN the_DT same_JJ
        herpesvirus_JJ subfamily_RB as_IN EBV_NNP ._. The_DT clinical_JJ studies_NNS do_VBP
        suggest_VBP that_IN there_EX may_MD be_VB a_DT relationship_NN between_IN CMV_NNP
        infection_NN and_CC EBV_NNP reactivation_NN ,_, and_CC the_DT 
        in_IN vitro_NN studies_NNS strengthen_VBP the_DT
        notion_NN of_IN potential_JJ herpesvirus-herpesvirus_JJ interactions_NNS
        occurring_VBG ._. However_RB ,_, the_DT effect_NN CMV_NNP and_CC EBV_NNP may_MD have_VB on_IN each_DT
        other_JJ has_VBZ not_RB specifically_RB been_VBN investigated_VBN ._. Therefore_RB
        this_DT study_NN examined_VBD an_DT 
        in_IN vitro_NN CMV_NNP superinfection_NN of_IN EBV_NNP
        latently_RB infected_JJ cell_NN lines_NNS (_( BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS )_) and_CC
        the_DT effect_NN on_IN EBV_NNP reactivation_NN ._. These_DT B-_NNP cell_NN lines_NNS were_VBD
        observed_VBN to_TO be_VB susceptible_JJ to_TO a_DT CMV_NNP superinfection_NN and_CC EBV_NNP
        reactivation_NN occurs_VBZ only_RB in_IN the_DT cell_NN lines_NNS superinfected_JJ
        with_IN CMV_NNP ._. The_DT observations_NNS in_IN this_DT study_NN support_NN the_DT
        previous_JJ 
        in_IN vivo_NN and_CC 
        in_IN vitro_NN findings_NNS by_IN showing_VBG that_IN
        potential_JJ interactions_NNS exist_VBP between_IN CMV_NNP and_CC EBV_NNP ._. Overall_RB ,_,
        these_DT data_NNS suggest_VBP CMV_NNP may_MD be_VB a_DT cofactor_NN in_IN EBV_NNP
        pathogenesis_NNS in_IN the_DT immunosuppressed_JJ patient_NN ._.
      
      
        Results_NNS
        
          CMV_NNP transcript_NN in_IN BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS
          The_DT CMV_NNP MIE_NNP transcript_NN was_VBD present_JJ in_IN the_DT BJAB-B_NNP 1_CD and_CC
          P_NN 3_CD HR-_NNP 1_CD cells_NNS superinfected_JJ with_IN CMV_NNP at_IN all_DT time_NN points_NNS as_IN
          shown_VBN by_IN the_DT real-time_JJ PCR_NNP data_NNS (_( Figures_NNS 1_CD Aand_NNP 2_CD A_DT ,_,
          respectively_RB )_) ._. CMV_NNP copy_NN standards_NNS were_VBD run_VBN for_IN
          calculation_NN of_IN the_DT standard_JJ curve_NN ._. The_DT CMV_NNP standards_NNS (_( 5_CD ×_NN
          10_CD 5_CD ,_, 5_CD ×_NN 10_CD 3_CD ,_, and_CC 5_CD ×_NN 10_CD 1_LS )_) for_IN the_DT BJAB-B_NNP 1_CD cells_NNS are_VBP
          shown_VBN (_( Figure_NN 1_CD C_NNP )_) and_CC the_DT standards_NNS for_IN the_DT P_NN 3_CD HR-_NNP 1_CD cells_NNS
          were_VBD not_RB shown_VBN ._. Agarose_NNP gel_NN analysis_NN was_VBD run_VBN only_RB with_IN
          the_DT BJAB-B_NNP 1_CD cells_NNS (_( Figure_NN 1_CD D_NNP )_) and_CC the_DT greatest_JJS amount_NN of_IN
          transcript_NN was_VBD observed_VBN at_IN 24_CD hours_NNS post_NN CMV_NNP
          superinfection_NN with_IN a_DT decline_NN in_IN the_DT latter_JJ time_NN points_NNS ._.
          BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS that_WDT were_VBD exposed_VBN to_TO
          UV-irradiated_NNP CMV_NNP had_VBD no_DT presence_NN of_IN the_DT CMV_NNP MIE_NNP
          transcript_NN ,_, indicating_VBG that_IN the_DT virus_NN was_VBD inactivated_JJ
          (_( Figures_NNS 1_CD Band_NNP 2_CD B_NNP ,_, respectively_RB )_) ._. The_DT uninfected_JJ cell_NN
          lines_NNS were_VBD negative_JJ for_IN the_DT CMV_NNP MIE_NNP transcript_NN and_CC show_NN
          that_IN the_DT CMV_NNP primers_NNS do_VBP not_RB cross-react_JJ with_IN EBV_NNP (_( data_NNS
          not_RB shown_VBN )_) ._. Table_NNP 1_CD (_( BJAB-B_NNP 1_LS )_) and_CC Table_NNP 2_CD (_( P_NN 3_CD HR-_NNP 1_LS )_) show_NN the_DT
          quantitative_JJ analyses_NNS calculated_VBN from_IN the_DT standard_JJ curve_NN ._.
          The_DT calculated_VBN starting_VBG quantity_NN (_( SQ_NNP )_) values_NNS given_VBN in_IN
          both_DT tables_NNS suggest_VBP that_IN these_DT cell_NN lines_NNS ,_, although_IN they_PRP
          are_VBP susceptible_JJ to_TO CMV_NNP ,_, do_VBP not_RB show_VB a_DT high_JJ amount_NN of_IN
          infection_NN ._. Mock_NNP RT-PCRs_NNP were_VBD performed_VBN in_IN which_WDT PCR_NNP grade_NN
          water_NN was_VBD substituted_VBN for_IN the_DT RT_NNP enzyme_NN ._. These_DT mock_JJ
          reactions_NNS served_VBD as_IN a_DT check_NN for_IN DNA_NNP contamination_NN and_CC the_DT
          mock_JJ RT-PCRs_NNP of_IN the_DT respective_JJ experimental_JJ groups_NNS were_VBD
          negative_JJ (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          CMV_NNP antigen_NN in_IN P_NN 3_CD HR-_NNP 1_CD and_CC BJAB-B_NNP 1_CD cells_NNS
          Immunofluorescent_NNP staining_VBG for_IN the_DT p_NN 52_CD antigen_NN was_VBD
          performed_VBN to_TO further_VB show_NN the_DT susceptibilities_NNS of_IN CMV_NNP in_IN
          the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cell_NN lines_NNS ._. The_DT p_NN 52_CD gene_NN expresses_VBZ
          a_DT DNA_NNP binding_JJ protein_NN that_WDT is_VBZ present_JJ in_IN the_DT nuclei_NN of_IN
          infected_JJ cells_NNS beginning_VBG in_IN the_DT early_JJ phase_NN of_IN infection_NN
          through_IN to_TO the_DT late_JJ phase_NN ._. All_DT time_NN points_NNS for_IN both_DT cell_NN
          lines_NNS (_( BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_LS )_) were_VBD positive_JJ for_IN p_NN 52_CD antigen_NN
          and_CC a_DT representative_NN slide_NN is_VBZ shown_VBN at_IN 24_CD hours_NNS post_NN CMV_NNP
          superinfection_NN (_( Figure_NN 3_CD Aand_NNP 4_CD A_DT ,_, respectively_RB )_) ._. All_DT
          BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS exposed_VBN to_TO UV-irradiated_NNP CMV_NNP
          were_VBD consistently_RB negative_JJ for_IN the_DT p_NN 52_CD antigen_NN indicating_VBG
          sufficient_JJ CMV_NNP inactivation_NN (_( Figures_NNS 3_CD Band_NNP 4_CD B_NNP ,_,
          respectively_RB )_) ._. The_DT uninfected_JJ cells_NNS from_IN both_DT cell_NN lines_NNS
          were_VBD also_RB negative_JJ showing_NN no_DT cross-reactivities_JJ with_IN CMV_NNP
          (_( data_NNS not_RB shown_VBN )_) ._. Flow_NNP cytometric_JJ analysis_NN was_VBD performed_VBN
          only_RB with_IN the_DT BJAB-B_NNP 1_CD cells_NNS ._. Data_NNS from_IN the_DT flow_NN
          experiments_NNS were_VBD able_JJ to_TO give_VB a_DT quantitative_JJ analysis_NN by_IN
          analyzing_VBG the_DT fluorescence_NN of_IN the_DT individual_JJ cells_NNS ._.
          Positive_JJ cells_NNS were_VBD determined_VBN by_IN subtracting_VBG the_DT
          background_NN fluorescence_NN of_IN the_DT uninfected_JJ samples_NNS from_IN
          either_DT the_DT superinfected_JJ cells_NNS or_CC cells_NNS exposed_VBN to_TO
          inactivated_JJ virus_NN ._. CMV_NNP p_NN 52_CD antigen_NN expression_NN (_( 575_CD cells_NNS )_)
          was_VBD observed_VBN beginning_VBG at_IN 72_CD hours_NNS compared_VBN to_TO a_DT
          background_NN staining_VBG of_IN 77_CD cells_NNS that_WDT were_VBD exposed_VBN to_TO
          inactivated_JJ CMV_NNP ._. Three_CD hundred_CD seventy_NN nine_CD and_CC 150_CD p_NN 52_CD
          positive_JJ cells_NNS were_VBD present_JJ at_IN 96_CD and_CC 168_CD hours_NNS ,_,
          respectively_RB ._. The_DT UV-irradiated_NNP CMV_NNP exposed_VBD cells_NNS had_VBD
          counts_NNS of_IN 34_CD and_CC 76_CD cells_NNS (_( 96_CD and_CC 168_CD hours_NNS ,_,
          respectively_RB )_) ._. Positive_JJ counts_NNS in_IN the_DT BJAB-B_NNP 1_CD cells_NNS
          exposed_VBN to_TO inactivated_JJ CMV_NNP represents_VBZ non-specific_JJ
          staining_VBG ._. 10_CD ,_, 000_CD cells_NNS were_VBD collected_VBN and_CC analyzed_VBN per_IN
          experimental_JJ group_NN ._. The_DT flow_NN cytometry_NN data_NNS is_VBZ summarized_VBD
          in_IN Table_NNP 3_CD ._. The_DT amount_NN of_IN CMV_NNP positive_JJ BJAB-B_NNP 1_CD cells_NNS ,_, as_RB
          also_RB observed_VBD in_IN the_DT real-time_JJ data_NN ,_, show_NN a_DT decrease_NN with_IN
          respect_NN to_TO time_NN ._. Both_DT the_DT transcript_NN data_NN as_RB well_RB as_IN the_DT
          p_NN 52_CD antigen_NN expression_NN data_NNS show_VBP that_IN the_DT BJAB-B_NNP 1_CD cells_NNS
          are_VBP susceptible_JJ to_TO a_DT CMV_NNP superinfection_NN and_CC there_EX was_VBD not_RB
          a_DT high_JJ amount_NN of_IN infection_NN ._. Qualitative_NNP analyses_NNS of_IN the_DT
          immunofluorescent_NN staining_VBG in_IN BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS
          also_RB show_VBP that_IN a_DT low_JJ amount_NN of_IN infection_NN was_VBD
          occurring_VBG ._.
        
        
          CMV_NNP undergoes_NNS an_DT abortive_JJ infection_NN in_IN BJAB-B_NNP 1_CD
          cells_NNS
          A_DT CMV_NNP abortive_JJ infection_NN was_VBD not_RB determined_VBN for_IN the_DT
          P_NN 3_CD HR-_NNP 1_CD cells_NNS ._. In_IN order_NN to_TO determine_VB if_IN CMV_NNP was_VBD undergoing_VBG
          an_DT abortive_JJ or_CC replicative_JJ infection_NN ,_, separate_JJ CMV_NNP
          superinfection_NN experiments_NNS were_VBD performed_VBN ._. Cells_NNP were_VBD
          washed_VBN after_IN 5_CD hours_NNS incubation_NN with_IN CMV_NNP and_CC fresh_JJ media_NNS
          was_VBD added_VBN ._. The_DT CMV_NNP infections_NNS were_VBD carried_VBN out_IN to_TO 10_CD
          days_NNS ._. Supernatants_NNP were_VBD taken_VBN immediately_RB after_IN washing_VBG
          to_TO show_VB absence_NN of_IN unattached_JJ CMV_NNP ._. Aliquots_NNP were_VBD taken_VBN at_IN
          24_CD and_CC 48_CD hours_NNS for_IN immunofluorescence_NN analysis_NN to_TO
          confirm_VB CMV_NNP infection_NN (_( data_NNS not_RB shown_VBN )_) ._. After_IN 10_CD days_NNS the_DT
          cells_NNS were_VBD vortexed_JJ and_CC supernatant_NN was_VBD collected_VBN and_CC
          placed_VBN into_IN cultures_NNS of_IN MRC-_NNP 5_CD fibroblasts_NNS ._. MRC-_NNP 5_CD
          infections_NNS were_VBD carried_VBN out_IN to_TO 10_CD days_NNS ._. No_DT CPE_NNP was_VBD
          observed_VBN in_IN any_DT of_IN the_DT fibroblast_NN infections_NNS ,_, suggesting_VBG
          that_IN an_DT abortive_JJ infection_NN was_VBD occurring_VBG in_IN the_DT BJAB-B_NNP 1_CD
          cells_NNS ._.
        
        
          EBV_NNP reactivation_NN after_IN CMV_NNP superinfections_NNS of_IN
          BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS
          This_DT project_NN has_VBZ shown_VBN that_IN the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD
          cells_NNS were_VBD susceptible_JJ to_TO a_DT CMV_NNP superinfection_NN by_IN
          detecting_VBG viral_JJ transcript_NN and_CC protein_NN ._. The_DT effect_NN on_IN EBV_NNP
          latency_NN was_VBD next_RB examined_VBD ._. The_DT BZLF_NNP 1_CD gene_NN product_NN ,_, Zebra_NNP
          (_( Zta_NNP )_) is_VBZ an_DT indicator_NN for_IN EBV_NNP reactivation_NN ._. PMA_NNP and_CC
          ionomycin_NN (_( 1_CD μg_NN /_NN ml_NN )_) non-specifically_JJ reactivates_NNS EBV_NNP and_CC
          was_VBD used_VBN as_IN a_DT positive_JJ control_NN for_IN BZLF_NNP 1_CD transcript_NN
          expression_NN in_IN the_DT cell_NN lines_NNS ._. The_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD
          cells_NNS were_VBD incubated_JJ with_IN PMA_NNP /_NN ionomycin_NN (_( 1_CD μg_NN /_NN ml_NN )_)
          (_( Figures_NNS 5_CD Aand_NNP 6_CD A_DT ,_, respectively_RB )_) ._. Presence_NNP of_IN the_DT BZLF_NNP 1_CD
          transcript_NN in_IN the_DT superinfected_JJ P_NN 3_CD HR-_NNP 1_CD cells_NNS was_VBD observed_VBN
          beginning_VBG at_IN 24_CD hours_NNS post_NN superinfection_NN ,_, decreased_VBD at_IN
          48_CD hours_NNS and_CC then_RB was_VBD observed_VBN to_TO increase_VB after_IN 72_CD hours_NNS
          (_( Figure_NN 6_CD B_NNP )_) ._. Detection_NNP of_IN BZLF_NNP 1_CD in_IN the_DT P_NN 3_CD HR-_NNP 1_CD cells_NNS was_VBD
          performed_VBN by_IN real-time_JJ PCR_NNP only_RB ._. BZLF_NNP 1_CD transcript_NN in_IN the_DT
          BJAB-B_NNP 1_CD cells_NNS was_VBD first_RB observed_VBD at_IN 48_CD hours_NNS post_NN CMV_NNP
          superinfection_NN and_CC was_VBD expressed_VBN through_IN to_TO 96_CD hours_NNS ,_, as_IN
          shown_VBN in_IN the_DT real-time_JJ PCR_NNP data_NNS (_( Figure_NN 5_CD B_NNP )_) ._. The_DT amount_NN
          of_IN BZLF_NNP 1_CD transcript_NN expression_NN in_IN the_DT BJAB-B_NNP 1_CD cells_NNS
          started_VBD to_TO decrease_VB after_IN 48_CD hours_NNS ._. Agarose_NNP gel_NN analysis_NN
          confirms_VBZ the_DT real-time_JJ PCR_NNP data_NNS and_CC shows_VBZ that_IN the_DT PCR_NNP
          was_VBD specific_JJ (_( Figure_NN 6_CD D_NNP )_) ._. Due_JJ to_TO the_DT relatively_RB low_JJ
          amount_NN of_IN the_DT BZLF_NNP 1_CD PCR_NNP product_NN in_IN the_DT real-time_JJ data_NN and_CC
          gel_NN analysis_NN ,_, it_PRP was_VBD expected_VBN that_IN the_DT immunofluorescence_NN
          staining_VBG would_MD be_VB minimal_JJ ._. Immunofluorescence_NNP analysis_NN
          was_VBD performed_VBN only_RB with_IN the_DT BJAB-B_NNP 1_CD cells_NNS and_CC the_DT
          experimental_JJ group_NN that_WDT was_VBD superinfected_JJ with_IN CMV_NNP was_VBD
          observed_VBN to_TO have_VB expression_NN of_IN the_DT BZLF_NNP 1_CD protein_NN at_IN 168_CD
          hours_NNS (_( Figure_NN 7_CD A_DT )_) ._. BJAB-B_NNP 1_CD cells_NNS stimulated_VBN with_IN
          PMA_NNP /_NN ionomycin_NN were_VBD used_VBN as_IN a_DT positive_NN IF_IN control_NN (_( Figure_NN
          7_CD B_NNP )_) ._. Uninfected_NNP and_CC UV-irradiated_NNP CMV_NNP treated_VBD cells_NNS
          showed_VBD no_DT expression_NN of_IN the_DT BZLF_NNP 1_CD transcript_NN or_CC protein_NN
          indicating_VBG no_DT EBV_NNP reactivation_NN (_( data_NNS not_RB shown_VBN )_) ._. Mock_NNP
          RT-PCRs_NNP were_VBD not_RB performed_VBN for_IN the_DT BZLF_NNP 1_CD PCR_NNP reactions_NNS
          because_IN the_DT primers_NNS recognize_VBP mRNA_NN ._.
        
        
          Glyceraldehyde-_NNP 3_CD -_: phosphate_NN dehydrogenase_NN
          (_( G_NNP 3_CD PDH_NNP )_)
          Amplification_NNP of_IN the_DT housekeeping_NN gene_NN G_NNP 3_CD PDH_NNP served_VBD as_IN
          a_DT control_NN for_IN RNA_NNP integrity_NN ._. The_DT product_NN was_VBD analyzed_VBN by_IN
          agarose_NN (_( 2_CD %_NN )_) gel_NN electrophoresis_NNS and_CC stained_JJ with_IN
          ethidium_NN bromide_NN ._. This_DT transcript_NN was_VBD present_JJ at_IN all_DT time_NN
          points_NNS among_IN all_DT experimental_JJ groups_NNS for_IN both_DT cell_NN lines_NNS
          (_( data_NNS not_RB shown_VBN )_) ._.
        
      
      
        Discussion_NNP
        This_DT study_NN has_VBZ shown_VBN that_IN the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cell_NN
        lines_NNS were_VBD susceptible_JJ to_TO a_DT CMV_NNP superinfection_NN ,_, and_CC a_DT low_JJ
        amount_NN of_IN infection_NN was_VBD observed_VBN ._. Numerous_JJ studies_NNS have_VBP
        been_VBN able_JJ to_TO show_VB that_IN PBMCs_NNP and_CC B-_NNP cells_NNS in_IN particular_JJ can_MD
        have_VB expression_NN of_IN viral_JJ transcript_NN and_CC /_NN or_CC antigen_NN [_NN 35_CD 36_CD
        37_CD 38_CD 39_CD 40_CD 41_CD ]_NN however_RB ,_, other_JJ studies_NNS have_VBP been_VBN
        contradictory_JJ [_NN 40_CD 42_CD ]_NN and_CC therefore_RB no_DT consensus_NN among_IN
        the_DT observations_NNS noted_VBD ._. Early_RB studies_VBZ have_VBP shown_VBN that_IN in_IN
        other_JJ B-_NNP cell_NN lines_NNS ,_, CMV_NNP DNA_NNP has_VBZ been_VBN observed_VBN [_NN 43_CD 44_CD 45_CD ]_NN
        ._. The_DT MOI_NNP used_VBD in_IN this_DT study_NN (_( 20_CD )_) indicates_VBZ that_IN there_EX were_VBD
        20_CD virus_NN particles_NNS per_IN BJAB-B_NNP 1_CD or_CC P_NN 3_CD HR-_NNP 1_CD cell_NN ._. This_DT high_JJ
        MOI_NNP would_MD have_VB seemed_VBN to_TO ensure_VB that_IN enough_RB CMV_NNP was_VBD present_JJ
        to_TO superinfect_NN the_DT respective_JJ cell_NN lines_NNS ._. However_RB ,_, despite_IN
        the_DT high_JJ MOI_NNP ,_, the_DT real-time_JJ PCR_NNP and_CC immunofluorescent_NN
        staining_VBG data_NNS from_IN the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS show_VBP low_JJ
        amounts_NNS of_IN infection_NN present_JJ ._.
        The_DT concept_NN of_IN this_DT study_NN was_VBD to_TO show_VB evidence_NN that_IN CMV_NNP
        can_MD superinfect_NN these_DT B-_NNP cell_NN lines_NNS and_CC may_MD induce_VB EBV_NNP
        reactivation_NN by_IN using_VBG a_DT standardized_JJ CMV_NNP preparation_NN ._.
        Infectivity_NNP differences_NNS have_VBP been_VBN observed_VBN between_IN clinical_JJ
        isolates_VBZ of_IN CMV_NNP and_CC laboratory_NN adapted_VBD strains_NNS ._. The_DT strain_NN
        used_VBN in_IN this_DT study_NN ,_, AD_NNP 169_CD ,_, and_CC the_DT Towne_NNP strains_NNS were_VBD both_DT
        used_VBN to_TO develop_VB vaccines_NNS [_NN 49_CD ]_NN ._. Differences_NNS in_IN
        infectivity_NN have_VBP been_VBN observed_VBN between_IN 2_CD of_IN the_DT same_JJ
        strains_NNS of_IN CMV_NNP and_CC this_DT may_MD be_VB attributed_VBN to_TO the_DT deletion_NN
        or_CC mutation_NN of_IN certain_JJ tropism_NN genes_NNS upon_IN extensive_JJ serial_NN
        propagation_NN [_NN 50_CD 51_CD ]_NN ._. Clinical_NNP isolates_VBZ (_( wild-type_JJ CMV_NNP )_)
        can_MD carry_VB more_JJR than_IN 220_CD genes_NNS ,_, and_CC some_DT of_IN these_DT genes_NNS can_MD
        be_VB lost_VBN by_IN deletion_NN and_CC /_NN or_CC rearrangement_NN during_IN laboratory_NN
        passage_NN [_NN 50_CD ]_NN ._. The_DT AD_NNP 169_CD strain_NN used_VBN in_IN this_DT study_NN has_VBZ
        been_VBN passaged_JJ many_JJ times_NNS and_CC because_IN of_IN these_DT variations_NNS
        observed_VBD among_IN the_DT CMV_NNP strains_NNS ,_, this_DT may_MD partly_RB account_VB for_IN
        the_DT low_JJ infectivity_NN observed_VBD in_IN the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD
        cells_NNS ._. Perhaps_RB an_DT increase_NN in_IN CMV_NNP infection_NN in_IN the_DT cell_NN
        lines_NNS could_MD have_VB been_VBN obtained_VBN with_IN the_DT use_NN of_IN a_DT clinical_JJ
        isolate_VB of_IN CMV_NNP ._. Our_PRP$ laboratory_NN is_VBZ currently_RB collecting_VBG
        clinical_JJ isolates_VBZ of_IN CMV_NNP for_IN future_JJ superinfection_NN
        experiments_NNS ._.
        The_DT first_JJ step_NN in_IN CMV_NNP infection_NN is_VBZ attachment_NN to_TO its_PRP$
        cellular_JJ target_NN ;_: however_RB ,_, the_DT receptors_NNS for_IN CMV_NNP have_VBP not_RB
        yet_RB been_VBN delineated_JJ ._. Heparin_NNP sulfate_NN and_CC CD_NNP 13_CD have_VBP been_VBN
        suggested_VBN to_TO be_VB involved_VBN in_IN CMV_NNP attachment_NN [_NN 52_CD 53_CD 54_CD ]_NN ._.
        Heparin_NNP sulfate_NN is_VBZ a_DT receptor_NN present_JJ on_IN many_JJ cell_NN types_NNS ,_,
        but_CC CD_NNP 13_CD is_VBZ not_RB expressed_VBN on_IN B-_NNP cells_NNS ._. Even_RB with_IN these_DT
        receptors_NNS being_VBG implicated_VBN as_IN requirements_NNS for_IN CMV_NNP
        adherence_NN and_CC penetration_NN ,_, the_DT wide_JJ range_NN of_IN cellular_JJ
        tropism_NN observed_VBD would_MD suggest_VB that_IN additional_JJ receptors_NNS
        might_MD be_VB used_VBN ._.
        The_DT detection_NN of_IN CMV_NNP protein_NN was_VBD performed_VBN to_TO further_VB
        show_NN CMV_NNP infection_NN in_IN the_DT cell_NN lines_NNS used_VBN ._. The_DT CMV_NNP p_NN 52_CD
        antigen_NN is_VBZ expressed_VBN in_IN the_DT early_JJ phase_NN of_IN infection_NN and_CC in_IN
        the_DT nuclei_NN of_IN infected_JJ cells_NNS ._. During_IN a_DT replicative_JJ
        infection_NN ,_, expression_NN of_IN this_DT protein_NN continues_VBZ through_IN to_TO
        the_DT late_JJ phase_NN of_IN infection_NN [_NN 56_CD ]_NN ._. One_CD function_NN of_IN the_DT
        p_NN 52_CD protein_NN is_VBZ to_TO aid_VB in_IN replication_NN by_IN binding_VBG to_TO the_DT
        viral_JJ DNA_NNP polymerase_NN ._. The_DT immunofluorescence_NN data_NN confirms_VBZ
        the_DT real-time_JJ PCR_NNP data_NNS showing_VBG that_IN BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD
        cells_NNS were_VBD susceptible_JJ to_TO a_DT CMV_NNP superinfection_NN and_CC a_DT low_JJ
        amount_NN of_IN infection_NN was_VBD observed_VBN ._. The_DT p_NN 52_CD expression_NN as_IN
        shown_VBN in_IN the_DT flow_NN cytometry_NN data_NNS of_IN the_DT BJAB-B_NNP 1_CD cells_NNS also_RB
        indicate_VBP that_IN a_DT low_JJ amount_NN of_IN infection_NN was_VBD observed_VBN ._. The_DT
        numbers_NNS of_IN p_NN 52_CD positive_JJ cells_NNS was_VBD also_RB observed_VBN to_TO decrease_VB
        with_IN respect_NN to_TO time_NN ,_, perhaps_RB indicating_VBG an_DT abortive_JJ
        infection_NN may_MD be_VB occurring_VBG ._. No_DT CPE_NNP was_VBD observed_VBN in_IN any_DT of_IN
        the_DT fibroblast_NN superinfection_NN studies_NNS indicating_VBG a_DT lack_NN of_IN
        extracellular_NN CMV_NNP infectious_JJ particles_NNS ._. We_PRP did_VBD not_RB test_VB for_IN
        cell_NN associated_VBN CMV_NNP in_IN these_DT experiments_NNS ,_, so_IN it_PRP is_VBZ possible_JJ
        that_DT virus_NN emerging_VBG from_IN the_DT infected_JJ B-_NNP cell_NN line_NN may_MD be_VB
        bound_VBN to_TO other_JJ cells_NNS in_IN the_DT culture_NN ._. However_RB ,_, the_DT fact_NN that_IN
        only_RB a_DT small_JJ percentage_NN of_IN the_DT B-_NNP cells_NNS showed_VBD evidence_NN of_IN
        CMV_NNP infection_NN along_IN with_IN the_DT lack_NN of_IN virus_NN in_IN the_DT
        supernatant_NN supports_VBZ the_DT probability_NN that_IN the_DT CMV_NNP infection_NN
        of_IN the_DT BJAB-B_NNP 1_CD cells_NNS represents_VBZ an_DT abortive_JJ infection_NN ._. The_DT
        data_NNS represented_VBD here_RB support_NN the_DT work_NN of_IN others_NNS showing_VBG
        that_IN CMV_NNP may_MD undergo_VB an_DT abortive_JJ infection_NN in_IN B-_NNP cells_NNS
        rather_RB than_IN a_DT productive_JJ one_CD [_NN 35_CD 36_CD 46_CD 47_CD 48_CD ]_NN ._.
        Regardless_RB of_IN whether_IN viable_JJ CMV_NNP or_CC UV-irradiated_NNP CMV_NNP is_VBZ
        used_VBN ,_, the_DT virus_NN still_RB can_MD attach_VB to_TO the_DT host_NN cell_NN and_CC cause_VB
        the_DT upregulation_NN of_IN cellular_JJ genes_NNS ,_, including_VBG
        proto-oncogenes_JJ [_NN 55_CD 57_CD 58_CD 59_CD ]_NN ._. It_PRP was_VBD observed_VBN in_IN this_DT
        study_NN that_IN the_DT UV-irradiated_NNP CMV_NNP had_VBD no_DT effect_NN on_IN BZLF_NNP 1_CD
        transcript_NN expression_NN ,_, suggesting_VBG that_IN the_DT effect_NN observed_VBD
        in_IN the_DT superinfected_JJ BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS was_VBD not_RB
        attachment_NN mediated_JJ and_CC infectious_JJ CMV_NNP is_VBZ at_IN least_RBS
        required_VBN ._. At_IN this_DT point_NN it_PRP has_VBZ not_RB been_VBN determined_VBN if_IN CMV_NNP
        acts_NNS directly_RB or_CC indirectly_RB to_TO cause_VB EBV_NNP reactivation_NN ._. A_DT
        direct_JJ effect_NN would_MD imply_VB that_IN a_DT CMV_NNP transactivator_NN is_VBZ
        produced_VBN that_WDT could_MD somehow_RB cause_VB the_DT expression_NN of_IN or_CC at_IN
        least_JJS aid_NN in_IN the_DT activation_NN of_IN the_DT BZLF_NNP 1_CD gene_NN ._. Flamand_NNP et_CC
        al_NN ._. observed_VBD that_IN HHV-_NNP 6_CD (_( same_JJ subfamily_RB as_IN CMV_NNP )_) could_MD cause_VB
        the_DT reactivation_NN of_IN EBV_NNP [_NN 33_CD ]_NN ._. The_DT authors_NNS suggested_VBD that_IN
        HHV-_NNP 6_CD was_VBD having_VBG a_DT direct_JJ effect_NN on_IN EBV_NNP reactivation_NN
        because_IN they_PRP were_VBD able_JJ to_TO observe_VB the_DT presence_NN of_IN both_DT
        viral_JJ antigens_NNS in_IN the_DT same_JJ cell_NN ._. However_RB ,_, this_DT observation_NN
        does_VBZ not_RB necessarily_RB suggest_VB direct_JJ activation_NN because_IN the_DT
        effect_NN cellular_JJ activation_NN may_MD have_VB on_IN EBV_NNP latency_NN is_VBZ not_RB
        known_VBN ._. There_EX may_MD be_VB some_DT as_RB yet_RB unknown_JJ host_NN cell_NN gene_NN or_CC
        genes_NNS that_WDT are_VBP activated_VBN or_CC upregulated_JJ in_IN association_NN with_IN
        HHV-_NNP 6_CD penetration_NN and_CC infection_NN ._. Obviously_RB the_DT same_JJ
        uncertainties_NNS can_MD be_VB applied_VBN to_TO the_DT CMV_NNP superinfections_NNS of_IN
        the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS ._.
        The_DT BZLF_NNP 1_CD gene_NN of_IN EBV_NNP is_VBZ an_DT immediate_JJ early_JJ gene_NN
        involved_VBN in_IN the_DT first_JJ step_NN of_IN EBV_NNP reactivation_NN ,_, and_CC its_PRP$
        activity_NN is_VBZ controlled_VBN at_IN the_DT transcriptional_NN level_NN [_NN 60_CD 61_CD
        62_CD 63_CD 64_CD 65_CD 66_CD ]_NN ,_, by_IN protein-protein_JJ interactions_NNS [_NN 64_CD 65_CD
        66_CD 67_CD 68_CD ]_NN ,_, and_CC phosphorylation_NN [_NN 64_CD 69_CD 70_CD ]_NN ._. Perhaps_RB CMV_NNP
        may_MD cause_VB the_DT activation_NN of_IN certain_JJ cellular_JJ kinases_NNS ,_, which_WDT
        in_IN turn_NN may_MD activate_VBP BZLF_NNP 1_CD transcript_NN expression_NN ._. CMV_NNP has_VBZ
        been_VBN shown_VBN to_TO cause_VB calcium_NN flow_NN and_CC protein_NN kinase_NN C_NNP (_( PKC_NNP )_)
        activation_NN that_WDT could_MD then_RB be_VB involved_VBN in_IN the_DT early_JJ
        activation_NN of_IN transcription_NN factors_NNS [_NN 71_CD ]_NN ._. Cellular_NNP
        levels_NNS of_IN secondary_JJ messengers_NNS inositol_NN 1_CD ,_, 4_CD ,_, 5_CD -_: triphosphate_NN
        and_CC 1_CD ,_, 2_CD -_: diacylglycerol_NN [_NN 71_CD 72_CD 73_CD ]_NN ,_, as_RB well_RB as_IN the_DT MAP_NNP
        kinases_NNS (_( ERK_NNP 1_CD and_CC ERK_NNP 2_LS )_) [_NN 74_CD 75_CD ]_NN are_VBP also_RB known_VBN to_TO be_VB
        upregulated_JJ ,_, which_WDT may_MD have_VB an_DT effect_NN on_IN EBV_NNP reactivation_NN ._.
        One_CD study_NN performed_VBD a_DT DNA_NNP microarray_NN analysis_NN on_IN CMV_NNP
        infected_JJ cells_NNS and_CC observed_VBD an_DT upregulation_NN of_IN 258_CD cellular_JJ
        mRNAs_NNS whose_WP$ level_NN changes_NNS were_VBD by_IN a_DT factor_NN of_IN 4_CD or_CC more_JJR
        after_IN the_DT onset_NN of_IN viral_JJ replication_NN [_NN 76_CD ]_NN ._. The_DT functions_NNS
        of_IN some_DT of_IN these_DT genes_NNS still_RB remains_VBZ highly_RB speculative_JJ ,_,
        yet_RB it_PRP gives_VBZ an_DT insight_NN as_IN to_TO what_WP potential_JJ roles_NNS these_DT
        genes_NNS may_MD play_VB ,_, particularly_RB in_IN EBV_NNP reactivation_NN ._.
        The_DT CMV_NNP transcript_NN expression_NN in_IN BJAB-B_NNP 1_CD cells_NNS was_VBD
        observed_VBN beginning_VBG at_IN 24_CD hours_NNS and_CC was_VBD expressed_VBN through_IN to_TO
        168_CD hours_NNS ._. The_DT BZLF_NNP 1_CD transcript_NN was_VBD observed_VBN beginning_VBG at_IN
        48_CD hours_NNS and_CC expressed_VBD though_IN 96_CD hours_NNS ._. There_EX was_VBD a_DT greater_JJR
        amount_NN of_IN CMV_NNP MIE_NNP transcript_NN present_JJ compared_VBN to_TO the_DT BZLF_NNP 1_CD
        transcript_NN in_IN the_DT BJAB-B_NNP 1_CD cells_NNS ._. BZLF_NNP 1_CD protein_NN expression_NN
        was_VBD observed_VBN only_RB at_IN 168_CD hours_NNS post_NN CMV_NNP superinfection_NN ._. CMV_NNP
        p_NN 52_CD protein_NN expression_NN was_VBD observed_VBN through_IN 168_CD hours_NNS post_NN
        superinfection_NN (_( immunofluorescence_NN and_CC flow_NN cytometry_NN data_NNS )_)
        and_CC p_NN 52_CD positive_JJ cells_NNS peaked_VBD at_IN 72_CD hours_NNS (_( flow_NN cytometry_NN )_) ._.
        Among_IN the_DT P_NN 3_CD HR-_NNP 1_CD cells_NNS ,_, the_DT CMV_NNP transcript_NN was_VBD also_RB
        expressed_VBN from_IN 96_CD hours_NNS to_TO 168_CD hours_NNS ;_: however_RB ,_, the_DT viral_JJ
        load_NN increases_NNS with_IN respect_NN to_TO time_NN as_IN opposed_VBN to_TO the_DT
        BJAB-B_NNP 1_CD cells_NNS ._. During_IN the_DT earlier_JJR time_NN points_NNS (_( 24_CD ,_, 48_CD ,_, and_CC
        72_CD hours_NNS )_) ,_, the_DT sample_NN curves_NNS have_VBP not_RB yet_RB crossed_VBN the_DT
        threshold_NN and_CC therefore_RB were_VBD not_RB included_VBN in_IN the_DT program_NN 's_POS
        final_JJ quantitative_JJ analysis_NN ._. The_DT BZLF_NNP 1_CD transcript_NN in_IN the_DT
        superinfected_JJ P_NN 3_CD HR-_NNP 1_CD cells_NNS shows_VBZ presence_NN at_IN 24_CD hours_NNS ,_,
        decreases_NNS at_IN subsequent_JJ time_NN points_NNS and_CC finally_RB peaks_NNS at_IN
        168_CD hours_NNS ._. Differences_NNS in_IN the_DT CMV_NNP and_CC BZLF_NNP 1_CD transcript_NN
        expression_NN between_IN the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS may_MD be_VB
        attributed_VBN to_TO the_DT fact_NN that_IN these_DT are_VBP different_JJ cell_NN lines_NNS ,_,
        despite_IN the_DT presence_NN of_IN EBV_NNP ._. The_DT kinetic_JJ expression_NN of_IN both_DT
        viral_JJ transcripts_NNS and_CC proteins_NNS in_IN the_DT respective_JJ cell_NN lines_NNS
        would_MD seem_VB to_TO suggest_VB that_IN CMV_NNP may_MD be_VB having_VBG an_DT indirect_JJ
        effect_NN on_IN EBV_NNP reactivation_NN through_IN the_DT participation_NN of_IN
        cellular_JJ factors_NNS ._.
        Despite_IN the_DT low_JJ infectivity_NN of_IN the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD
        cells_NNS by_IN CMV_NNP ,_, EBV_NNP reactivation_NN was_VBD observed_VBN in_IN the_DT
        experimental_JJ groups_NNS superinfected_JJ with_IN CMV_NNP ._. The_DT cell_NN lines_NNS
        that_WDT were_VBD exposed_VBN to_TO UV-irradiated_NNP CMV_NNP had_VBD no_DT indication_NN of_IN
        BZLF_NNP 1_CD transcript_NN or_CC protein_NN suggesting_VBG that_IN the_DT effect_NN on_IN
        EBV_NNP reactivation_NN was_VBD not_RB attachment_NN mediated_JJ and_CC that_IN
        infectious_JJ CMV_NNP was_VBD required_VBN ._. 
        In_IN vivo_NN ,_, it_PRP would_MD be_VB difficult_JJ to_TO
        pinpoint_VB one_CD specific_JJ factor_NN to_TO cause_VB the_DT switch_NN from_IN
        latency_NN to_TO lytic_JJ infection_NN ._. However_RB ,_, 
        in_IN vitro_NN ,_, it_PRP was_VBD most_RBS interesting_JJ to_TO
        observe_VB EBV_NNP reactivation_NN only_RB in_IN the_DT cell_NN lines_NNS that_WDT were_VBD
        superinfected_JJ with_IN CMV_NNP ._.
        A_DT CMV_NNP infection_NN ,_, 
        in_IN vivo_NN ,_, can_MD contribute_VB to_TO the_DT net_JJ
        immunosuppressive_JJ status_NN of_IN the_DT immunocompromised_JJ patient_NN [_NN
        11_CD ]_NN ._. A_DT CMV_NNP infection_NN can_MD result_VB in_IN the_DT production_NN of_IN
        certain_JJ immune_JJ effector_NN proteins_NNS (_( cytokines_NNS and_CC chemokines_NNS )_)
        that_WDT may_MD affect_VB latency_NN in_IN the_DT EBV_NNP infected_JJ B-_NNP cells_NNS [_NN 77_CD ]_NN
        ._. The_DT production_NN of_IN these_DT cytokines_NNS and_CC chemokines_NNS from_IN a_DT
        CMV_NNP superinfected_JJ BJAB-B_NNP 1_CD or_CC P_NN 3_CD HR-_NNP 1_CD cell_NN may_MD affect_VB
        neighboring_VBG cells_NNS and_CC therefore_RB cause_VB EBV_NNP reactivation_NN ,_,
        implying_VBG that_IN CMV_NNP could_MD be_VB having_VBG an_DT indirect_JJ effect_NN on_IN EBV_NNP
        latency_NN ._.
      
      
        Conclusions_NNP
        Because_IN CMV_NNP infection_NN and_CC disease_NN is_VBZ such_JJ an_DT important_JJ
        concern_NN among_IN the_DT immunosuppressed_JJ patient_NN populations_NNS
        (_( transplant_NN and_CC HIV_NNP infected_JJ individuals_NNS )_) ,_, its_PRP$ involvement_NN
        in_IN the_DT reactivation_NN of_IN EBV_NNP must_MD be_VB considered_VBN ._. This_DT report_NN
        has_VBZ shown_VBN that_IN BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD cells_NNS ,_, both_DT latently_RB
        infected_VBN with_IN EBV_NNP ,_, were_VBD susceptible_JJ to_TO a_DT CMV_NNP superinfection_NN
        and_CC only_RB in_IN the_DT experimental_JJ groups_NNS that_WDT were_VBD superinfected_JJ
        with_IN CMV_NNP were_VBD there_EX any_DT indication_NN of_IN EBV_NNP reactivation_NN ._.
        These_DT data_NNS support_VBP the_DT clinical_JJ studies_NNS showing_VBG an_DT 
        in_IN vivo_NN relationship_NN between_IN a_DT CMV_NNP
        active_JJ infection_NN and_CC EBV_NNP reactivation_NN ._. Although_IN it_PRP would_MD be_VB
        very_RB difficult_JJ to_TO prove_VB that_IN a_DT CMV_NNP infection_NN is_VBZ the_DT cause_NN
        of_IN EBV_NNP reactivation_NN in_IN clinical_JJ situations_NNS due_JJ to_TO the_DT gamut_NN
        of_IN factors_NNS that_WDT are_VBP involved_VBN ,_, the_DT fact_NN that_IN EBV_NNP
        reactivation_NN was_VBD observed_VBN after_IN 
        in_IN vitro_NN CMV_NNP superinfections_NNS supports_VBZ
        this_DT role_NN ._. Inducers_NNP of_IN EBV_NNP replication_NN are_VBP of_IN importance_NN
        because_IN of_IN the_DT serious_JJ complications_NNS that_WDT are_VBP associated_VBN
        with_IN recurrent_JJ EBV_NNP infections_NNS ,_, particularly_RB in_IN
        immunosuppressed_JJ individuals_NNS ._. Since_IN a_DT majority_NN of_IN the_DT
        population_NN is_VBZ seropositive_JJ for_IN CMV_NNP ,_, reactivation_NN of_IN CMV_NNP in_IN
        immunosuppressed_JJ patients_NNS may_MD further_VB accentuate_NN the_DT
        reactivation_NN of_IN EBV_NNP therefore_RB contributing_VBG to_TO the_DT
        proliferation_NN of_IN EBV_NNP infected_JJ B-_NNP cells_NNS ._. The_DT results_NNS in_IN this_DT
        project_NN suggest_VBP that_IN CMV_NNP may_MD contribute_VB as_IN a_DT co-factor_JJ in_IN
        EBV_NNP pathogenesis_NNS ._. More_RBR detailed_JJ molecular_JJ studies_NNS are_VBP
        needed_VBN to_TO examine_VB the_DT direct_JJ and_CC /_NN or_CC indirect_JJ effects_NNS CMV_NNP
        may_MD have_VB on_IN EBV_NNP ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Cells_NNP and_CC virus_NN
          P_NN 3_CD HR-_NNP 1_CD (_( ATCC_NNP )_) and_CC BJAB-B_NNP 1_CD cells_NNS (_( generously_RB donated_VBN by_IN
          Dr_NNP ._. George_NNP Miller_NNP )_) are_VBP EBV_NNP latently_RB infected_JJ B-_NNP cells_NNS kept_VBD
          in_IN RPMI_NNP 1640_CD medium_NN (_( supplemented_JJ with_IN 10_CD %_NN FBS_NNP and_CC an_DT
          antibiotic-mycotic_JJ solution_NN )_) (_( Gibco_NNP ,_, Invitrogen_NNP Corp_NNP ._. ,_,
          Carlsbad_NNP ,_, CA_NNP )_) ._. The_DT AD_NNP 169_CD laboratory_NN strain_NN of_IN CMV_NNP was_VBD
          from_IN the_DT clinical_JJ virology_NN laboratory_NN (_( Tampa_NNP General_NNP
          Hospital_NNP ,_, Tampa_NNP ,_, FL_NNP )_) ,_, and_CC used_VBD for_IN the_DT superinfections_NNS ._.
          CMV_NNP was_VBD grown_VBN and_CC harvested_VBN from_IN MRC-_NNP 5_CD fibroblast_NN
          cultures_NNS (_( Biowhittaker_NNP ,_, Walkersville_NNP ,_, MD_NNP )_) and_CC
          concentrated_VBN by_IN ultra-centrifugation_JJ (_( 28000_CD g_SYM for_IN 60_CD
          minutes_NNS at_IN 4_CD °_NN C_NNP )_) ._. The_DT CMV_NNP titer_NN was_VBD determined_VBN using_VBG the_DT
          shell_NN vial_NN assay_NN ._. Briefly_NNP ,_, this_DT is_VBZ an_DT immunofluorescence_NN
          assay_NN in_IN which_WDT 1_CD :_: 10_CD dilutions_NNS of_IN the_DT virus_NN were_VBD prepared_VBN
          in_IN shell_NN vials_NNS and_CC incubated_JJ at_IN 37_CD °_NN C_NNP overnight_JJ ._. The_DT MRC-_NNP 5_CD
          cells_NNS in_IN the_DT shell_NN vials_NNS were_VBD fixed_VBN and_CC permeabilized_JJ for_IN
          15_CD minutes_NNS in_IN methanol_NN :_: acetone_NN (_( 1_CD :_: 1_LS )_) and_CC then_RB washed_VBN in_IN
          PBS_NNP (_( Bartels_NNP Inc_NNP ._. ,_, Intracel_NNP Corp_NNP ._. ,_, Frederick_NNP ,_, MD_NNP ,_,
          reconstituted_JJ in_IN 1_CD liter_NN of_IN Millipore_NNP water_NN ,_, pH_NN 7_CD ._. 0_CD -_: 7_CD ._. 6_CD )_) ._.
          The_DT cells_NNS were_VBD stained_JJ with_IN a_DT FITC_NNP labelled_JJ antibody_NN
          directed_VBN against_IN the_DT major_JJ immediate_JJ early_JJ antigen_NN (_( MIE_NNP )_)
          (_( Chemicon_NNP ,_, Temecula_NNP ,_, CA_NNP )_) and_CC visualized_JJ using_VBG a_DT
          fluorescent_NN microscope_NN ._. Each_DT green_JJ (_( positive_JJ )_) cell_NN was_VBD
          counted_VBN as_IN one_CD viral_JJ particle_NN ._.
        
        
          CMV_NNP superinfection_NN of_IN the_DT BJAB-B_NNP 1_CD and_CC P_NN 3_CD HR-_NNP 1_CD
          cells_NNS
          500_CD ,_, 000_CD cells_NNS were_VBD counted_VBN using_VBG the_DT Cell-_NNP DYN_NNP 4000_CD
          (_( Abbott_NNP Systems_NNPS ,_, Abbott_NNP Park_NNP ,_, IL_NNP )_) and_CC placed_VBN in_IN a_DT 24_CD -_: well_RB
          culture_NN plate_NN with_IN RPMI_NNP 1640_CD medium_NN ._. The_DT P_NN 3_CD HR-_NNP 1_CD and_CC
          BJAB-B_NNP 1_CD cells_NNS were_VBD infected_JJ at_IN a_DT multiplicity_NN of_IN
          infection_NN (_( MOI_NNP )_) of_IN 20_CD and_CC were_VBD either_CC uninfected_JJ ,_,
          infected_JJ ,_, or_CC exposed_VBD to_TO UV-irradiated_NNP virus_NN ._. CMV_NNP was_VBD
          exposed_VBN to_TO UVC_NNP light_JJ for_IN 2_CD hours_NNS in_IN our_PRP$ biological_JJ safety_NN
          cabinet_NN ._. The_DT experiments_NNS were_VBD carried_VBN out_IN for_IN 7_CD days_NNS and_CC
          samples_NNS were_VBD taken_VBN at_IN 24_CD ,_, 48_CD ,_, 72_CD ,_, 96_CD ,_, and_CC 168_CD hours_NNS ._. Time_NN
          points_NNS for_IN the_DT P_NN 3_CD HR-_NNP 1_CD cells_NNS were_VBD the_DT same_JJ except_IN for_IN an_DT
          additional_JJ time_NN point_NN at_IN 120_CD hours_NNS ._. At_IN each_DT time_NN point_NN ,_,
          cells_NNS were_VBD analyzed_VBN by_IN immunofluorescence_NN and_CC real-time_JJ
          reverse_NN transcriptase-polymerase_JJ chain_NN reaction_NN (_( RT-PCR_NNP )_) ._.
          The_DT P_NN 3_CD HR-_NNP 1_CD cells_NNS were_VBD not_RB subjected_VBN to_TO flow_VB cytometric_JJ
          analysis_NN ._. Superinfections_NNP were_VBD repeated_VBN three_CD times_NNS and_CC
          data_NNS shown_VBN are_VBP representative_NN experiments_NNS ._.
        
        
          MRC-_NNP 5_CD fibroblast_NN infection_NN of_IN supernatants_NNS from_IN CMV_NNP
          superinfections_NNS
          Separate_NNP superinfection_NN experiments_NNS of_IN the_DT BJAB-B_NNP 1_CD
          cells_NNS were_VBD set_VBN up_RP and_CC were_VBD incubated_JJ with_IN CMV_NNP for_IN 5_CD hours_NNS
          to_TO allow_VB for_IN viral_JJ attachment_NN ._. The_DT cells_NNS were_VBD then_RB washed_VBN
          to_TO remove_VB any_DT unattached_JJ virus_NN and_CC fresh_JJ medium_NN was_VBD
          added_VBN ._. The_DT CMV_NNP superinfections_NNS were_VBD carried_VBN out_IN to_TO 10_CD
          days_NNS ._. The_DT cultures_NNS were_VBD vortexed_JJ ,_, supernatant_NN was_VBD
          collected_VBN ,_, and_CC added_VBD to_TO cultures_NNS of_IN MRC-_NNP 5_CD fibroblasts_NNS ._.
          Supernatant_NNP fluid_NN was_VBD collected_VBN immediately_RB after_IN
          infection_NN and_CC washing_VBG to_TO establish_VB that_IN any_DT unattached_JJ
          CMV_NNP was_VBD not_RB present_JJ ._. MRC-_NNP 5_CD fibroblasts_NNS were_VBD examined_VBN for_IN
          CPE_NNP ._.
        
        
          Immunofluorescent_NNP staining_VBG for_IN p_NN 52_CD (_( CMV_NNP )_) and_CC BZLF_NNP 1_CD
          (_( EBV_NNP )_)
          Aliquots_NNP of_IN 100_CD μl_NN (_( approximately_RB 50_CD ,_, 000_CD cells_NNS )_) from_IN
          each_DT experimental_JJ group_NN were_VBD subjected_VBN to_TO a_DT cytospin_NN and_CC
          fixed_VBN and_CC permeabilized_JJ similarly_RB to_TO the_DT shell_NN vial_NN
          assay_NN ._. The_DT anti-p_JJ 52_CD and_CC anti-_NN BZLF_NNP 1_CD antibodies_NNS (_( Dako_NNP
          Corporation_NNP ,_, Carpinteria_NNP ,_, CA_NNP )_) were_VBD prepared_VBN according_VBG to_TO
          package_NN inserts_NNS ._. Evan_NNP 's_POS Blue_NNP was_VBD added_VBN to_TO the_DT final_JJ p_NN 52_CD
          solution_NN ._. The_DT p_NN 52_CD antibody_NN was_VBD directly_RB labelled_JJ with_IN
          FITC_NNP (_( fluorescein_NN isothiocyanate_NN )_) and_CC did_VBD not_RB require_VB a_DT
          secondary_JJ antibody_NN step_NN ._. The_DT BZLF_NNP 1_CD antibody_NN is_VBZ unlabelled_JJ
          and_CC required_VBD a_DT secondary_JJ goat_NN anti-mouse_JJ antibody_NN
          labelled_JJ with_IN FITC_NNP ._. The_DT secondary_JJ antibody_NN was_VBD diluted_VBN
          1_CD :_: 200_CD in_IN PBS_NNP and_CC Evan_NNP 's_POS Blue_NNP was_VBD added_VBN ._. The_DT primary_JJ and_CC
          secondary_JJ antibodies_NNS were_VBD incubated_JJ in_IN a_DT humidified_JJ
          chamber_NN at_IN 37_CD °_NN C_NNP for_IN 30_CD minutes_NNS ._. The_DT slides_NNS were_VBD washed_VBN in_IN
          PBS_NNP after_IN each_DT incubation_NN step_NN ,_, prepared_VBN with_IN mounting_VBG
          media_NNS ,_, and_CC visualized_JJ under_IN a_DT fluorescent_NN microscope_NN ._.
        
        
          Flow_NNP cytometry_NN of_IN p_NN 52_CD antigen_NN
          Aliquots_NNP of_IN 300_CD μl_NN (_( approximately_RB 150_CD ,_, 000_CD cells_NNS )_) were_VBD
          placed_VBN in_IN 5_CD -_: ml_NN Falcon_NNP tubes_NNS and_CC washed_VBN in_IN PBS_NNP ._. The_DT cells_NNS
          were_VBD fixed_VBN and_CC permeabilized_JJ with_IN pre-made_JJ solutions_NNS from_IN
          Caltag_NNP Laboratories_NNPS (_( Burlingame_NNP ,_, CA_NNP )_) (_( Fix_NNP &_CC Perm_NNP )_)
          according_VBG to_TO kit_NN instructions_NNS ._. During_IN the_DT
          permeabilization_NN step_NN ,_, FITC-labelled_NNP antibody_NN (_( p_NN 52_CD )_) was_VBD
          added_VBN at_IN a_DT 1_CD :_: 5_CD dilution_NN ._. Cells_NNP were_VBD washed_VBN in_IN PBS_NNP and_CC
          then_RB 750_CD μl_NN of_IN paraformaldehyde_NN was_VBD added_VBN and_CC read_VB on_IN the_DT
          FACScalibur_NNP flow_NN cytometer_NN (_( Becton_NNP Dickinson_NNP ,_, Los_NNP
          Angeles_NNP ,_, CA_NNP )_) ._. Fluorescence_NNP parameters_NNS were_VBD set_VBN with_IN
          regards_VBZ to_TO infected_JJ and_CC uninfected_JJ samples_NNS ._. CMV_NNP infected_JJ
          and_CC uninfected_JJ MRC-_NNP 5_CD fibroblasts_NNS were_VBD used_VBN as_IN positive_JJ
          controls_NNS for_IN viable_JJ CMV_NNP and_CC antibody_NN staining_VBG ._. 10_CD ,_, 000_CD
          BJAB-B_NNP 1_CD cells_NNS were_VBD first_JJ separated_JJ according_VBG to_TO size_NN and_CC
          granularity_NN (_( forward_RB vs_NNS ._. side_NN scatter_NN )_) on_IN a_DT dot_VBP plot_NN ._.
          Viable_NNP cells_NNS were_VBD then_RB selected_VBN and_CC gated_JJ for_IN further_JJ
          analysis_NN on_IN a_DT histogram_NN for_IN FL_NNP 1_CD (_( FITC_NNP ,_, p_NN 52_CD antigen_NN )_)
          versus_CC cell_NN counts_NNS ._. The_DT final_JJ histogram_NN analyses_NNS involved_VBD
          subtracting_VBG background_NN of_IN the_DT corresponding_JJ mock-infected_JJ
          cells_NNS from_IN the_DT BJAB-B_NNP 1_CD cells_NNS superinfected_JJ with_IN CMV_NNP or_CC
          UV-irradiated_NNP CMV_NNP ._. Analysis_NNP was_VBD performed_VBN using_VBG the_DT
          CellQuest_NNP software_NN (_( Becton_NNP Dickinson_NNP ,_, Los_NNP Angeles_NNP ,_, CA_NNP )_) ._.
          The_DT P_NN 3_CD HR-_NNP 1_CD cells_NNS were_VBD not_RB analysed_JJ by_IN flow_NN cytometry_NN ._.
        
        
          RNA_NNP extraction_NN and_CC isolation_NN
          The_DT nucleic_JJ acid_NN isolation_NN was_VBD performed_VBN on_IN an_DT
          automated_VBN extractor_NN from_IN the_DT Organon_NNP Tekinika_NNP Corporation_NNP
          (_( Boxtel_NNP ,_, Netherlands_NNP )_) and_CC the_DT extractions_NNS were_VBD performed_VBN
          according_VBG to_TO kit_NN instructions_NNS modified_VBN from_IN the_DT method_NN by_IN
          Boom_NNP et_CC al_NN ._. [_NN 78_CD ]_NN ._. All_DT reagents_NNS used_VBN for_IN extractions_NNS
          were_VBD from_IN the_DT company_NN ._. Aliquots_NNP of_IN 400_CD μl_NN (_( approximately_RB
          200_CD ,_, 000_CD cells_NNS )_) were_VBD used_VBN per_IN experimental_JJ time_NN point_NN ._. The_DT
          final_JJ result_NN was_VBD approximately_RB 50_CD μl_NN of_IN nucleic_JJ acid_NN in_IN
          elution_NN buffer_NN ._. The_DT nucleic_JJ acid_NN samples_NNS were_VBD then_RB
          subjected_VBN to_TO DNase_NNP treatment_NN and_CC RNA_NNP clean_VB up_IN with_IN
          Ambion_NNP 's_POS (_( Austin_NNP ,_, TX_NNP )_) DNA-free_NNP kit_NN following_VBG their_PRP$
          provided_VBN protocol_NN ._.
        
        
          RNA_NNP quantitation_NN
          Using_VBG Ribogreen_NNP dye_NN and_CC RNA_NNP quantitation_NN standards_NNS
          from_IN Molecular_NNP Probes_NNP (_( Eugene_NNP ,_, OR_NNP )_) ,_, the_DT amount_NN of_IN RNA_NNP in_IN
          the_DT experimental_JJ samples_NNS were_VBD calculated_VBN ._. Briefly_NNP ,_, an_DT
          aliquot_NN of_IN the_DT RNA_NNP samples_NNS were_VBD diluted_VBN 1_CD :_: 100_CD in_IN TE_NNP
          buffer_NN ._. RNA_NNP standards_NNS were_VBD prepared_VBN (_( 4000_CD ,_, 2000_CD ,_, 1000_CD ,_,
          500_CD ,_, 250_CD ,_, and_CC 125_CD ng_NN )_) ._. The_DT Ribogreen_NNP dye_NN was_VBD diluted_VBN
          1_CD :_: 200_CD in_IN TE_NNP buffer_NN and_CC 20_CD μl_NN of_IN the_DT diluted_VBN RNA_NNP (_( standard_NN
          or_CC sample_NN )_) was_VBD mixed_VBN with_IN 20_CD μl_NN of_IN the_DT diluted_VBN Ribogreen_NNP
          dye_NN ._. Samples_NNP and_CC standards_NNS were_VBD placed_VBN in_IN a_DT microtiter_NN
          plate_NN and_CC read_VB on_IN the_DT CytoFluor_NNP reader_NN from_IN Applied_NNP
          Biosystems_NNP (_( Foster_NNP City_NNP ,_, CA_NNP )_) (_( excitation_NN 485_CD nm_NN /_NN 20_CD nm_NN and_CC
          emission_NN 530_CD nm_NN /_NN 25_CD nm_NN )_) ._. The_DT standard_JJ curve_NN and_CC sample_NN
          quantitations_NNS were_VBD determined_VBN using_VBG an_DT Excel_NNP
          spreadsheet_NN ._.
        
        
          Reverse_VBP transcription_NN
          RNA_NNP for_IN cDNA_NN production_NN was_VBD performed_VBN using_VBG Promega_NNP 's_POS
          (_( Madison_NNP ,_, WI_NNP )_) random_JJ hexamers_NNS ,_, RNAsin_NNP ,_, RT_NNP buffer_NN ,_, and_CC RT_NNP
          enzyme_NN ._. For_IN each_DT sample_NN ,_, the_DT RNA_NNP (_( 2_CD μg_NN )_) was_VBD initially_RB
          incubated_JJ with_IN the_DT random_JJ hexamers_NNS (_( 0_CD ._. 5_LS μg_NN )_) and_CC enough_RB
          PCR_NNP grade_NN water_NN to_TO bring_VB the_DT volume_NN up_IN to_TO 20_CD μl_NN ._.
          Incubation_NNP of_IN the_DT RNA_NNP and_CC random_JJ hexamers_NNS was_VBD performed_VBN
          at_IN 95_CD °_NN C_NNP for_IN 5_CD minutes_NNS and_CC then_RB held_VBN at_IN 4_CD °_NN C_NNP ._. The_DT RT_NNP mix_NN
          included_VBD 5_CD ._. 6_CD μl_NN of_IN 5_CD X_NNP RT_NNP buffer_NN ,_, 0_CD ._. 02_CD mM_NN of_IN dNTPs_NNS (_( with_IN
          dTTP_NN ,_, not_RB dUTP_NN ,_, Perkin_NNP Elmer_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP )_) ,_, 14_CD ._. 22_CD
          units_NNS of_IN AMV_NNP RT_NNP enzyme_NN ,_, and_CC 20_CD units_NNS of_IN RNAsin_NNP per_IN
          reaction_NN ._. A_DT total_NN of_IN 9_CD ._. 68_CD μl_NN of_IN the_DT RT_NNP mix_NN was_VBD added_VBN to_TO
          the_DT RNA_NNP samples_NNS (_( with_IN the_DT random_JJ hexamers_NNS )_) and_CC then_RB
          subjected_VBN to_TO RT_NNP cycle_NN conditions_NNS (_( 42_CD °_NN C_NNP for_IN 45_CD minutes_NNS ,_,
          95_CD °_NN C_NNP for_IN 5_CD minutes_NNS and_CC a_DT 4_CD °_NN C_NNP hold_VB )_) ._. All_DT incubations_NNS were_VBD
          done_VBN on_IN BioRad_NNP 's_POS iCycler_NN (_( Richmond_NNP ,_, CA_NNP )_) ._. Mock_NNP RTs_NNP were_VBD
          set_VBN up_RP in_IN which_WDT PCR_NNP grade_NN water_NN was_VBD substituted_VBN for_IN the_DT
          RT_NNP enzyme_NN as_IN a_DT check_NN for_IN DNA_NNP contamination_NN ._.
        
        
          Real-time_NNP PCR_NNP
          The_DT PCR_NNP mix_NN per_IN reaction_NN included_VBD 10_CD μl_NN SYBR_NNP Green_NNP
          buffer_NN ,_, 1_CD ._. 5_CD mM_NN MgCl_NNP 
          2_CD ,_, 1_CD μM_NN dNTP_NN mix_NN (_( with_IN dUTP_NN )_) ,_, 0_CD ._. 5_CD μl_NN
          CMV_NNP primer_NN mix_NN ,_, 2_CD ._. 5_CD units_NNS Ampli_NNP 
          Taq_NNP gold_NN ,_, 0_CD ._. 05_CD units_NNS of_IN
          uracil-_NN N-_NNP glycosylase_NN (_( UNG_NNP ,_, Epicentre_NNP ,_, Madison_NNP ,_, WI_NNP )_) that_WDT
          had_VBD been_VBN diluted_VBN 1_CD :_: 10_CD in_IN UNG_NNP buffer_NN ,_, and_CC molecular_JJ grade_NN
          water_NN to_TO bring_VB the_DT volume_NN up_IN to_TO 45_CD μl_NN with_IN the_DT addition_NN
          of_IN 5_CD μl_NN of_IN cDNA_NN or_CC standard_JJ ._. The_DT PCR_NNP reagents_NNS were_VBD
          obtained_VBN from_IN Perkin_NNP Elmer_NNP ._. The_DT CMV_NNP primers_NNS ,_, from_IN
          Synthetic_NNP Genetics_NNP ,_, Inc_NNP ._. (_( San_NNP Diego_NNP ,_, CA_NNP )_) ,_, amplify_VB the_DT MIE_NNP
          gene_NN ._. The_DT BZLF_NNP 1_CD primers_NNS recognize_VBP only_RB mRNA_NN and_CC the_DT
          sequences_NNS are_VBP 5_CD '_POS -_: TTCCACAGCCTGCACCAGTG-_NNP 3_CD '_POS and_CC
          5_CD '_POS -_: GGCAGCAGCCACCTCACGGT-_NNP 3_CD '_POS [_NN 79_CD ]_NN ._. Primers_NNP were_VBD
          generated_VBN by_IN Sigma_NNP Genosys_NNP (_( The_DT Woodlands_NNP ,_, TX_NNP )_) ._. The_DT CMV_NNP
          PCR_NNP was_VBD quantitative_JJ and_CC the_DT BZLF_NNP 1_CD PCR_NNP was_VBD qualitative_JJ ._.
          The_DT PCR_NNP consisted_VBD of_IN 2_CD pre-incubation_JJ steps_NNS ,_, 37_CD °_NN C_NNP /_NN 15_CD
          minutes_NNS and_CC 95_CD °_NN C_NNP /_NN 10_CD minutes_NNS (_( for_IN UNG_NNP activation_NN and_CC UNG_NNP
          denaturation_NN /_NN 
          Taq_NNP activation_NN )_) ._. The_DT cycles_NNS for_IN PCR_NNP
          were_VBD 95_CD °_NN C_NNP /_NN 30_CD seconds_NNS ,_, 55_CD °_NN C_NNP /_NN 30_CD seconds_NNS ,_, and_CC 72_CD °_NN C_NNP /_NN 30_CD
          seconds_NNS for_IN 35_CD cycles_NNS ._. CMV_NNP DNA_NNP copy_NN standards_NNS (_( Synthetic_NNP
          Genetics_NNP ,_, Inc_NNP ._. )_) were_VBD used_VBN to_TO set_VB up_RP a_DT standard_JJ curve_NN ._.
          Standards_NNP were_VBD 500000_CD ,_, 5000_CD ,_, and_CC 50_CD CMV_NNP DNA_NNP copies_NNS ._.
          Dilutions_NNP were_VBD set_VBN up_RP using_VBG PCR_NNP grade_NN water_NN ._. The_DT software_NN
          (_( Bio-_NNP Rad_NNP ,_, Richmond_NNP ,_, CA_NNP )_) calculated_VBD the_DT standard_JJ curve_NN as_RB
          well_RB as_IN determined_VBD the_DT amount_NN of_IN CMV_NNP DNA_NNP in_IN the_DT
          superinfected_JJ samples_NNS ._. Agarose_NNP (_( 2_CD %_NN )_) gel_NN electrophoresis_NNS
          was_VBD performed_VBN in_IN order_NN to_TO determine_VB the_DT specificity_NN of_IN
          the_DT PCR_NNP reactions_NNS in_IN the_DT BJAB-B_NNP 1_CD cells_NNS only_RB ._. Primers_NNP and_CC
          positive_JJ control_NN for_IN the_DT glyceraldehyde-_NN 3_CD -_: phosphate_NN
          dehydrogenase_NN housekeeping_NN gene_NN were_VBD from_IN Clontech_NNP (_( BD_NNP
          Biosciences_NNP Clontech_NNP ,_, Palo_NNP Alto_NNP ,_, CA_NNP )_) ._. PCR_NNP recipe_NN and_CC
          conditions_NNS were_VBD run_VBN according_VBG to_TO the_DT included_VBN protocol_NN ._.
          G_NNP 3_CD PDH_NNP transcripts_NNS from_IN both_DT cell_NN lines_NNS were_VBD analyzed_VBN on_IN a_DT
          2_CD %_NN agarose_NN gel_NN only_RB ._.
        
        
          Real-time_NNP PCR_NNP analysis_NN
          The_DT instrument_NN camera_NN took_VBD numerous_JJ fluorescence_NN
          readings_NNS during_IN the_DT annealing_VBG stages_NNS and_CC displayed_VBD the_DT
          average_JJ reading_NN for_IN that_DT particular_JJ cycle_NN ._. At_IN the_DT end_NN of_IN
          the_DT PCR_NNP cycling_NN ,_, the_DT base_NN line_NN fluorescence_NN was_VBD
          calculated_VBN and_CC all_PDT the_DT samples_NNS were_VBD normalized_JJ to_TO zero_CD ._.
          The_DT threshold_NN level_NN (_( C_NNP 
          T_NN )_) was_VBD set_VBN at_IN a_DT point_NN when_WRB the_DT
          standards_NNS or_CC positive_JJ control_NN were_VBD in_IN its_PRP$ respective_JJ
          exponential_NN phase_NN of_IN amplification_NN ._. The_DT C_NNP 
          T_NN value_NN is_VBZ the_DT cycle_NN number_NN in_IN which_WDT a_DT
          sample_NN 's_POS fluorescence_NN crosses_VBZ the_DT set_VBN threshold_NN level_NN ,_,
          and_CC therefore_RB is_VBZ called_VBN positive_JJ ._. During_IN quantitative_JJ
          analysis_NN ,_, the_DT standard_JJ curve_NN was_VBD calculated_VBN and_CC the_DT
          sample_NN concentrations_NNS were_VBD derived_VBN from_IN the_DT curve_NN ._. All_DT
          calculations_NNS were_VBD performed_VBN with_IN the_DT included_VBN
          software_NN ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        RCA_NNP performed_VBD all_DT assays_NNS ,_, drafted_VBD the_DT manuscript_NN ,_, and_CC
        participated_VBD in_IN the_DT conception_NN of_IN this_DT project_NN ._. RHW_NNP also_RB
        participated_VBD in_IN the_DT conception_NN as_RB well_RB as_IN real-time_JJ PCR_NNP and_CC
        flow_NN cytometry_NN analyses_NNS ._.
        All_DT authors_NNS have_VBP read_VBN and_CC approved_VBD the_DT final_JJ
        manuscript_NN ._.
      
    
  
